Cardiovascular Mortality
Total CVD deaths during early period of pandemic highest since 2003
Heart disease remained among the leading causes of death, even amid the COVID-19 pandemic, which may have exacerbated preexisting CVD morbidity-related racial/ethnic disparities, researchers reported.
Extended VTE anticoagulation reduces major adverse cardiovascular event risk
Patients with venous thromboembolism treated with anticoagulants for more than 3 months had a lower risk for major adverse cardiovascular events, according to a study published in CHEST.
Presence of type 2 diabetes in acromegaly increases mortality and morbidity risks
Among adults with acromegaly, concomitant type 2 diabetes was associated with increased risks for overall mortality and for cardiovascular mortality and morbidity, researchers reported in The Journal of Clinical Endocrinology & Metabolism.
Combined remote monitoring, consultation reduces CV death, hospitalizations in HF
Telemedicine interventions that include remote disease monitoring and remote consultations may reduce short-term CV-related hospitalization and death risk among adults with HF, researchers reported in a meta-analysis.
High cardiorespiratory fitness reduces veterans’ death risk regardless of age, sex, race
In a cohort of U.S. veterans, high cardiorespiratory fitness was linked to lower risk for mortality across all age, sex and race groups, researchers reported.
Higher visceral adiposity index score linked to increased risk for all-cause mortality
Adults with a higher visceral adiposity index score have an increased risk for all-cause mortality as well as some cause-specific mortalities, according to data from the UK Biobank.
Exogenous hyper-, hypothyroidism increase risk for CV mortality
Both exogenous hyperthyroidism and exogenous hypothyroidism were linked to an elevated risk for cardiovascular mortality, according to results published in JAMA Network Open.
Risk for major adverse CV events elevated with type 2 diabetes, cognitive impairment
Adults with type 2 diabetes and cognitive impairment are more likely to experience major adverse cardiovascular events, stroke or CV mortality compared with those without cognitive impairment, according to study findings.
Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability
Swedish men diagnosed with type 1 diabetes in youth had higher all-cause and cardiovascular mortality risks compared with those without diabetes, and cognitive ability did not influence the associations, according to study data.
Fenofibrate may lower heart failure hospitalization, CV mortality in type 2 diabetes
In a cohort of patients with type 2 diabetes treated with simvastatin, fenofibrate decreased the composite of heart failure hospitalizations or cardiovascular mortality, according to an analysis of the ACCORD Lipid trial.